We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Blood Glucose System Maker Asks High Court To Decide Who Institutes Inter Partes Review

Mealey's (October 13, 2016, 5:43 PM EDT) -- WASHINGTON, D.C. — A manufacturer of a blood glucose monitoring system on Sept. 20 petitioned the U.S. Supreme Court to decide whether the Leahy-Smith America Invents Act (AIA) permits the Patent Trial and Appeal Board instead of the director of the U.S. Patent and Trademark Office to make inter partes review (IPR) institution decisions (LifeScan Scotland Ltd. v. Pharmatech Solutions Inc. and Michelle K. Lee, Director, U.S. Patent and Trademark Office, No. 16-377, U.S. Sup.).

(Petition for writ of certiorari available.  Document #78-161017-001B.)

LifeScan Scotland Ltd....
To view the full article, register now.